NextFin

Novartis Writes Down $1.9 Billion Avidity Drug but Raises Profit Outlook as Shares Rise

Summarized by NextFin AI
  • Novartis booked a $1.9 billion partial impairment on del-desiran, the muscle-wasting therapy central to its $12 billion Avidity Biosciences acquisition, yet shares rose about 2 percent.
  • Q3 2026 net sales reached $14.52 billion, up 4 percent constant-currency, with core EPS of $2.46 up 9 percent and core operating income rising 11 percent to $6.04 billion, lifting core margin to 41.6 percent.
  • Management upgraded full-year core operating income guidance to in line to low single-digit growth from a prior low single-digit decline, while leaving sales outlook unchanged, signaling margin expansion.
  • Priority brands drove growth with Kisqali up 37 percent, Scemblix up 67 percent, Leqvio up 63 percent, and Kesimpta up 22 percent, offsetting generic erosion from Entresto and future Xolair patent losses.

NextFin News - Novartis booked a $1.9 billion partial impairment on del-desiran, the muscle-wasting therapy at the center of its $12 billion acquisition of Avidity Biosciences, yet raised its full-year profit outlook and watched its shares climb about 2 percent. The split verdict from the Swiss drugmaker's third-quarter results is the clearest signal yet that investors are willing to forgive a blockbuster bet gone wrong - provided the rest of the machine keeps printing growth.

On October 27, 2026, Novartis reported third-quarter net sales of $14.52 billion, up 4 percent on a constant-currency basis, and core earnings per share of $2.46, up 9 percent. Core operating income rose 11 percent to $6.04 billion, pushing the core margin to 41.6 percent of sales. Against that backdrop, management did something unusual: it upgraded its full-year core operating income guidance to "in line to grow low single-digit" at constant currencies, from a previous forecast of a low single-digit decline, while leaving its sales outlook unchanged. The implication is that margins, not just revenue, are doing more work than the market had expected.

Buried inside the reported numbers was the cost of a failed bet. Reported operating income fell 59 percent to $1.84 billion and reported net income dropped 70 percent to $1.19 billion, driven mainly by a $1.9 billion partial impairment charge against the del-desiran in-process research and development asset. The market's reaction - shares rising on a day a $1.9 billion write-down hit the income statement - is the story. It says investors have already mourned del-desiran, and are now pricing Novartis on what still works.

The Writedown Was Old News by the Time It Hit the Books

The impairment did not arrive as a surprise. It was the accounting recognition of an economic loss the market had already absorbed nearly two months earlier, on September 8, when Novartis disclosed that del-desiran had failed to beat placebo in the Phase III HARBOR study for myotonic dystrophy type 1. The global trial of roughly 150 patients, running 54 weeks, did not demonstrate a statistically significant improvement on its primary endpoint of video hand opening time - a novel, machine-learning-based measure of hand myotonia. That day, Novartis shares fell about 10 percent, dropping as much as 11 percent intraday in their worst session on record and wiping out roughly 24 billion Swiss francs, or about $29.6 billion, of market value before paring the loss.

That sequencing matters. An impairment charge is not a cash outflow; it is a confession that an asset on the balance sheet is worth less than the company previously claimed. By the time the $1.9 billion hit the third-quarter income statement, the economic reality behind it - that del-desiran's commercial prospects had sharply dimmed - had been public for nearly two months. Investors were not reacting to the charge on October 27. They were reacting to everything else in the release, and to management's willingness to raise guidance despite it.

Novartis did not write the asset down to zero. The company described the charge as a "partial impairment" of the del-desiran IPR&D asset, which means management still sees a development path and a residual value worth carrying. On the results call, CEO Vas Narasimhan said:

"We saw evidence of clinical activity in the data and are working through the development path for this medicine."

The company has said it will engage with health authorities to determine the next steps for the program. A partial write-down, rather than a full one, is itself a statement of faith - and it keeps the question of further charges alive.

The Raise, Not the Charge, Is What Investors Priced

The more consequential number in the release was the guidance upgrade. Novartis now expects full-year core operating income to be broadly in line with 2025 or to grow by a low single-digit percentage at constant currencies, compared with its prior expectation of a low single-digit decline. Sales guidance was left at low single-digit growth. With the top-line forecast unchanged, the upgrade is a margin call: the company is telling investors that productivity efforts and a richer product mix are flowing through to the bottom line faster than expected.

The engine behind that confidence is visible in the brand-level data. Sales growth in the quarter was driven by a cohort of priority brands that are still in their expansion phase: Kisqali, the breast-cancer franchise, grew 37 percent; Kesimpta, for multiple sclerosis, rose 22 percent; Scemblix, for chronic myeloid leukemia, jumped 67 percent; Leqvio, the twice-yearly cholesterol injection, surged 63 percent; and Cosentyx added 9 percent. Together they are doing the job Novartis has long said they must do: replacing the revenue that generic competition is stripping from aging franchises.

The replacement math is not yet finished. Volume growth contributed 14 percentage points to third-quarter sales, while generic competition subtracted 9 percentage points and pricing subtracted 1 point. In other words, the new products are growing fast enough to more than cover the erosion - but the erosion is not slowing. Entresto, once the company's crown-jewel heart drug, continues to lose ground to U.S. generics, and Xolair faces the same cliff later this decade. The guidance upgrade is a bet that the launch curve of the new cohort stays steep enough, for long enough, to outrun the patent losses.

Free cash flow, the one soft spot in an otherwise firm release, fell 18 percent to $5.1 billion in the quarter, from $6.2 billion a year earlier, as higher R&D spending and working-capital movements weighed on operating cash flow. That is worth watching: a company that is raising its profit outlook while its cash generation slows is asking investors to trust accrual-based earnings quality. For a single quarter it is noise; across several quarters it would be a trend.

What the $1.9 Billion Charge Leaves Behind

The del-desiran impairment is best understood as the first concrete accounting consequence of Novartis's $12 billion acquisition of Avidity Biosciences, announced in October 2025. The deal - the largest of CEO Vas Narasimhan's tenure and the Swiss group's biggest in more than a decade - paid $72 a share in cash, a 46 percent premium to Avidity's prior close, for a San Diego biotech built around a single technology: antibody-oligonucleotide conjugates, or AOCs, designed to deliver RNA therapies into muscle tissue. After the transaction closes, Avidity's early-stage precision cardiology programs will be separated into a new publicly traded company called Spinco; Novartis is buying the neuromuscular franchise, not the heart assets.

Del-desiran was the platform's lead asset and its most important validation test. With it down, the Avidity thesis now rests on a narrower base. The company's Duchenne muscular dystrophy candidate, del-zota, has received priority review from the U.S. Food and Drug Administration - the fastest review track, reserved for therapies that could offer a meaningful advance over existing options. A second asset, del-brax, is in development for facioscapulohumeral muscular dystrophy and, per management, continues to progress. But the margin for error inside a $12 billion platform has just shrunk.

The timing of the setback also landed in a bruising week for the pipeline. Days before the del-desiran readout, Novartis disclosed that pelacarsen, its experimental cholesterol-lowering therapy, had failed the Phase III Lp(a)HORIZON cardiovascular outcomes trial, showing no significant reduction in cardiovascular events versus placebo. Two of the three major clinical catalysts the company had flagged for the year had now failed within days of each other. The del-desiran miss is not an isolated R&D accident; it is part of a cluster that has forced investors to re-examine how much of Novartis's mid-term growth story depends on assets that have not yet proven themselves in late-stage trials.

There is a valuation asymmetry here that the market has not fully resolved. On the first-quarter earnings call, management said the del-desiran miss had "no impact on the peak sales forecast," which it continued to place above $5 billion. The $1.9 billion partial impairment suggests a more sober internal view: a company that still expected a $5 billion drug would not typically carve out nearly $2 billion of value from its books. Either the peak-sales estimate will be revised down, or the remaining carrying value on the program is carrying an optimism premium that could face another charge if the development path narrows further.

Analysts had priced del-desiran with more skepticism than management. Before the HARBOR readout, Barclays estimated peak annual sales of $3.1 billion and assigned the drug a 60 percent probability of success following encouraging Phase II results. Guggenheim Securities, in a July note, described del-desiran, pelacarsen and remibrutinib as "critical" to Novartis's post-2030 growth. With two of the three now failed, the burden of validating the Avidity platform has shifted decisively onto del-zota.

Cyclical Charge, Structural Question

The impairment itself is cyclical - an accounting event, one-time, non-cash, and already reflected in the share price. Big pharmaceutical companies write down failed assets every year; it is the normal cost of doing R&D at scale, and Novartis's core earnings power is large enough to absorb a $1.9 billion charge without blinking. That is the case for treating October 27 as a non-event for the stock, and it is why the shares rose.

The structural question is different, and it is not answered by a single quarter of strong core earnings. Novartis bought Avidity because it needs new growth before Entresto and Xolair lose patent protection later this decade. The company has guided to a 5 to 6 percent compound annual sales growth rate through 2030, and that target now leans more heavily on the remaining Avidity assets than it did before September. A platform acquisition is only as good as its hit rate. With del-desiran failed and pelacarsen failed, the AOC technology that justified a $12 billion price tag has one major readout - del-zota in Duchenne - carrying a disproportionate share of the validation burden.

The counter-thesis is straightforward and deserves its weight. Novartis is a $14.5 billion-per-quarter company with a 41.6 percent core margin and a deep late-stage pipeline beyond Avidity: remibrutinib posted positive Phase III results in relapsing multiple sclerosis during the quarter, and the company notched regulatory wins for Rhapsido and Pluvicto in the United States. A single failed asset in a diversified portfolio should not shake confidence in a management team that has repeatedly shown it can replace lost revenue. From this angle, the impairment is a sign of accounting discipline, not strategic weakness - write it down, take the hit, and redirect capital to what works. The market's 2 percent rise is the sound of investors agreeing.

Both readings can be true at once, separated by time horizon. In the short term, the writedown is priced, the core business is compounding, and the guidance raise is a genuine positive. In the medium term, the test is whether del-zota wins approval and whether del-brax reads out cleanly - because a second impairment on the Avidity assets would change the conversation from "contained R&D loss" to "platform risk." In the long term, the structural question is whether Novartis can keep its 5 to 6 percent growth target intact as its two largest franchises face generic entry, using a combination of launches and acquisitions that have, so far, produced more headlines than approved blockbusters.

What to Watch

The falsifying signal is specific: if del-zota fails to secure FDA approval in Duchenne muscular dystrophy, or if del-brax misses its next pivotal endpoint, the remaining carrying value on the del-desiran program and the broader Avidity platform thesis would face a second, likely larger, impairment. That would test whether the market's forgiveness on October 27 was wisdom or premature.

On the core business side, watch whether free cash flow recovers in the fourth quarter after the 18 percent third-quarter decline, and whether Kisqali and Kesimpta can sustain growth rates above 20 percent as their bases get larger. The guidance raise is only as good as the quarters that follow it.

Novartis has made its position clear: the del-desiran readout was not what it had hoped for, but the rest of the machine is working well enough to raise the year's profit forecast anyway. The market agreed - for now. The writedown is the price of a failed bet; the raise is the bill for the next one, and it comes due with del-zota's regulatory decision.

Explore more exclusive insights at nextfin.ai.

Search, ask or analyze anything...